Amarin Corporation plc AMRN, a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the United States Patent and
Trademark Office (USPTO) has published notification of a Notice of Allowance
for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable
Pharmaceutical Compositions and Methods of Using the Same." This application
includes claims intended to protect the proposed Vascepa^® (icosapent ethyl)
indication based on Amarin's Phase 3 ANCHOR clinical trial results. In late
February, Amarin filed a Supplemental New Drug Application for the Vascepa
ANCHOR indication with the U.S. Food and Drug Administration (FDA), and
expects an FDA action date on the application before the end of 2013.
A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. Amarin plans to list this patent in the
FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or
Orange Book, after issuance of the patent and the anticipated approval of
Vascepa in the ANCHOR indication.
The claims in this allowed application relate to the planned Vascepa ANCHOR
indication and cover methods of treating mixed dyslipidemia through the daily
administration of 2500 mg to 5000 mg of highly pure EPA to a subject on any
statin therapy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in